ALIQOPA

Israel - English - Ministry of Health

Buy It Now

Active ingredient:
COPANLISIB AS DIHYDROCHLORIDE
Available from:
BAYER ISRAEL LTD
ATC code:
L01XX61
Pharmaceutical form:
POWDER FOR CONCENTRATED SOLUTION FOR INFUSION
Composition:
COPANLISIB AS DIHYDROCHLORIDE 60 MG/VIAL
Administration route:
I.V
Prescription type:
Required
Manufactured by:
BAYER AG, GERMANY
Therapeutic area:
COPANLISIB
Therapeutic indications:
Aliqopa is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Authorization number:
165 45 35773 00
Authorization date:
2020-10-01

Similar products

Search alerts related to this product

Share this information